Abstract
Intro: Inflammatory Bowel disease (IBD) is a recognised cause of bronchiectasis (BR). A prior multicentre study suggested IBD-BR patients had a 2 fold increased risk of mortality. There are however few large studies of patients with IBD-BR. We interrogated the EMBARC dataset to define the prevalence of reported IBD-BR.
Methods: Prospective observational cohort across Europe and Israel. We compared cross-sectional demographic data and quality of life results between IBDBR and all other causes of BR. We also modelled exacerbation frequency and lung function decline rates from our longitudinal data.
Results: From 11024 patients we identified 232 patients (2%) with reported IBD (Ulc Colitis=165, Crohn’s Disease=67). No significant differences in age, BMI, FEV1, exacerbation frequency or bronchiectasis severity index between groups were noted (all p>0.05). Quality of life respiratory symptom scores were significantly worse in IBDBR vs others (mean 54 vs 58, p=0.02). The relationship was stronger when IBDBR was compared to idiopathic BR alone (mean difference 5.6 points, p=0.001). P. aeruginosa was less common in IBD (18.8%) vs 22.8% in other aetiologies (p=0.009). Patients with IBD were not more likely to be treated with ICS (p=0.4). Exacerbation frequency was not significantly different between IBDBR and other BR: negative binomial IRR 1.07 95% CI 0.83-1.37; p=0.6) Similarly yearly lung function decline was not different with a 51mls year decline (linear model, +28mls to -131mls; p=0.2). Discussion IBD-BR may be skewed towards a more inflammatory rather than infective pathophysiology- The prognostic effect of IBD-BR in EMBARC is awaited. Supported by EU/EFPIA IMI iABC grant agreement 115721
Footnotes
Cite this article as: European Respiratory Journal 2018 52: Suppl. 62, PA2678.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2018